Survival of acid-adapted Salmonella typhimurium in fermented millet and acidified broth at different storage temperatures

Salmonella typhimurium KSN 533 was adapted to acid by exposure to lactic acid at pH 5.0 for 18 h. Subsequently, acid-adapted and non-adapted cells were challenged with lactic acid (pH 3.8) in Brain-heart infusion (BHI) at 4°C and 30°C. Acid-adapted and non-adapted cells were also inoculated into already fermented millet broth (pH 3.8) and at beginning of millet fermentation with Lactobacillus fermentum starter culture. Survival curves of acid-adapted and non-adapted cells at pH 3.8 were fitted with the Weibull distribution model. Acid-adapted cells were generally resistant to subsequent acid stress than non-adapted cells. Regardless of adaptation, cells were more sensitive to acid shock (pH 3.8) at 30°C than at 4°C storage. Whereas both acid-adapted and non-adapted S. typhimurium cells survived in appreciable numbers of 5.5 and 3.5 log cfu/ml respectively after 72 h storage at 4°C, no viable cells were detected for both acid-adapted and non-adapted cells after 12 an 9 h respectively at 30°C. Acid-adaptation induced protection against lethal acid and cross protection against cold stresses. Regardless of adaptation, viable population of Salmonella showed a slight increase during the early stages of millet fermentation. Similar inactivation rates were observed for both acid-adapted and non-adapted cells when inoculated at the beginning of fermentation. Thus acid adaptation does not appear to influence survival of S. typhimurium when inoculated at the beginning of the fermentation although acid-adapted cells survived better in already fermented millet. Keywords: acid-adaptation, millet fermentation, Salmonella, lethal acid challeng

Preliminary studies on the response of onion (Allium cepa L.) to planting depth and NPK fertilizer application

AbstrActStudies were conducted at the department of Agronomy of the University fordevelopmentStudies in Nyankpala,ghana, from July tooctober 2011 and repeated in the same period in2012 to determine the response of onion to depth of planting and fertilizer application.onionbulbs of average fresh weight of 24 g were planted 0, 2, 4 and 6 cm deep from soil surface, andNPK (15:15:15) fertilizer at the rate of 0, 85, 170 and 255 kg ha-1was applied at the time ofplanting and 2 weeks after planting.the treatment combinations were replicated four times inrandomized complete block (rCb) design.the results indicated that planting 4 cm deep, andapplying NPK fertilizer at the rate of 85 kg ha-1produced the highest bulb size and fresh weightat harvest.bulbs planted 2 cm deep, which received no fertilizer application, produced the high-est number of bulbs at harvest, whilst those planted at the depth of 6 cm and fertilized with 170kg ha-1of NPK gave the least number of bulbs. Leaf production was highest when bulbs wereplanted 2 cm deep, and no NPK fertilizer application.tiller production was also highest whenbulbs were planted 4 cm deep and no NPK fertilizer application. In onion production, therefore,whilst NPK fertilizer may not be required for vegetative growth, it is important to apply thefertilizer to enhance bulb production. onion growers in the study area should plant onion bulbson Nyankpala soil series 4 cm deep, and apply NPK fertilizer at the rate of 85 kg ha-1to the soilfor good bulb yield.Original scientific paper. Received 03 Apr 14; revised 16 Sept 14

Lowered Serum Triglyceride Levels among Chronic Hepatitis B-Infected Patients in Ghana

Dyslipidemia is a common finding in most studies of liver diseases. Little is however known about the effect of the two pathological stages of chronic hepatitis B (CHB) infection – chronicsymptomatic and asymptomatic – on the distribution of serum lipids in CHB infection. We conducted a study on CHB-infected patients attending specialist care at the Gastro-Intestinal (GI) Clinic at the Komfo Anokye Teaching Hospital (KATH) during a 7-month period. 64 participants were randomly sampled over the period. On the basis of serological and liver enzyme assays, participants were categorised as chronic asymptomatic, chronic symptomatic and healthy individuals. The relationship between the hosts pathological stage of infection were evaluated with the indices of lipid metabolism – LDL, HDL, triglyceride, and total serum cholesterol using ANOVA. The 64 volunteers recruited in the study were found to consist of 18 patients (28.1%) who were chronic symptomatic, 35 patients (54.7%) who were chronic asymptomatic hepatitis B, and 11 (17.2%) were healthy subjects. Significant overall male dominance was observed among all categories of population enrolled (p=0.0063). Serum triglyceride levels decreased more among the CHB-infected population compared to the healthy individuals (p=0.0010) with value lowest among the chronic symptomatic population. Basal serum cholesterol, HDL, and LDL were unaffected by the disease. This work reveals that serum triglyceride is significantly lowered in CHB infection and that the extent of this decrease in host is independent of the pathological stage of the infection.Keywords: chronic hepatitis B, lipid metabolism, triglyceride, chronic symptomati

Health Risk Assessment of Organochlorine Pesticides Contaminations in Dairy Products from Selected Farms in Greater Accra Region-Ghana

The study was geared towards ascertaining the levels of synthetic pyrethroids and organochlorine pesticides residues in dairy products(milk, cheese and yoghurt) from selected farms in Greater Accra Region of Ghana. In all fifty (50) samples of dairy products (25 fresh cow milk, 9 cheese and 16 yoghurt) were analyzed. Detectable levels of organochlorine pesticides,OCPs(β-HCH, endrin, endosulfan, p’p’-DDT, heptachlor and methoxychlor) and Synthetic pyrethroids(permethrin, allethrin, cypermethrin, deltamethrin and cyfluthrin). Ultrasonic extraction was employed and extract clean-up was done using silica gel and analyzed using a gas chromatograph (Agilent Model 6890 Gas Chromatograph) equipped with Ni-63 electron capture detector (ECD). . Milk samples were found to be the most contaminated with respect to the OCPs and the levels ranged between 0.0001μg/ml and 0.0407μg/ml. β-HCH was the highest OCP with concentration of 0.0407μg/ml while Cyfluthrin was the highest synthetic pyrethroids recorded in yoghurt sample (0.0318μg/ml).The levels of organochlorine pesticide residues detected in all the tissues were below the accepted Maximum Residue Limits (MRL), as adopted by the WHO/FAO Codex Alimentarius Commission (2005). Keywords: dairy products, organochlorine pesticides, synthetic pyrethroid, health risk, Ghana, gas chromatograph

The application of a biometric identification technique for linking community and hospital data in rural Ghana

Background: The reliability of counts for estimating population dynamics and disease burdens in communities depends on the availability of a common unique identifier for matching general population data with health facility data. Biometric data has been explored as a feasible common identifier between the health data and sociocultural data of resident members in rural communities within the Kintampo Health and Demographic Surveillance System located in the central part of Ghana. Objective: Our goal was to assess the feasibility of using fingerprint identification to link community data and hospital data in a rural African setting. Design: A combination of biometrics and other personal identification techniques were used to identify individual's resident within a surveillance population seeking care in two district hospitals. Visits from resident individuals were successfully recorded and categorized by the success of the techniques applied during identification. The successes of visits that involved identification by fingerprint were further examined by age. Results: A total of 27,662 hospital visits were linked to resident individuals. Over 85% of those visits were successfully identified using at least one identification method. Over 65% were successfully identified and linked using their fingerprints. Supervisory support from the hospital administration was critical in integrating this identification system into its routine activities. No concerns were expressed by community members about the fingerprint registration and identification processes. Conclusions: Fingerprint identification should be combined with other methods to be feasible in identifying community members in African rural settings. This can be enhanced in communities with some basic Demographic Surveillance System or census information

HIV/AIDS-related mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sites

BACKGROUND: As the HIV/AIDS pandemic has evolved over recent decades, Africa has been the most affected region, even though a large proportion of HIV/AIDS deaths have not been documented at the individual level. Systematic application of verbal autopsy (VA) methods in defined populations provides an opportunity to assess the mortality burden of the pandemic from individual data. OBJECTIVE: To present standardised comparisons of HIV/AIDS-related mortality at sites across Africa and Asia, including closely related causes of death such as pulmonary tuberculosis (PTB) and pneumonia. DESIGN: Deaths related to HIV/AIDS were extracted from individual demographic and VA data from 22 INDEPTH sites across Africa and Asia. VA data were standardised to WHO 2012 standard causes of death assigned using the InterVA-4 model. Between-site comparisons of mortality rates were standardised using the INDEPTH 2013 standard population. RESULTS: The dataset covered a total of 10,773 deaths attributed to HIV/AIDS, observed over 12,204,043 person-years. HIV/AIDS-related mortality fractions and mortality rates varied widely across Africa and Asia, with highest burdens in eastern and southern Africa, and lowest burdens in Asia. There was evidence of rapidly declining rates at the sites with the heaviest burdens. HIV/AIDS mortality was also strongly related to PTB mortality. On a country basis, there were strong similarities between HIV/AIDS mortality rates at INDEPTH sites and those derived from modelled estimates. CONCLUSIONS: Measuring HIV/AIDS-related mortality continues to be a challenging issue, all the more so as anti-retroviral treatment programmes alleviate mortality risks. The congruence between these results and other estimates adds plausibility to both approaches. These data, covering some of the highest mortality observed during the pandemic, will be an important baseline for understanding the future decline of HIV/AIDS

Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019

Background: The sustainable development goals (SDGs) aim to end HIV/AIDS as a public health threat by 2030. Understanding the current state of the HIV epidemic and its change over time is essential to this effort. This study assesses the current sex-specific HIV burden in 204 countries and territories and measures progress in the control of the epidemic. Methods: To estimate age-specific and sex-specific trends in 48 of 204 countries, we extended the Estimation and Projection Package Age-Sex Model to also implement the spectrum paediatric model. We used this model in cases where age and sex specific HIV-seroprevalence surveys and antenatal care-clinic sentinel surveillance data were available. For the remaining 156 of 204 locations, we developed a cohort-incidence bias adjustment to derive incidence as a function of cause-of-death data from vital registration systems. The incidence was input to a custom Spectrum model. To assess progress, we measured the percentage change in incident cases and deaths between 2010 and 2019 (threshold >75% decline), the ratio of incident cases to number of people living with HIV (incidence-to-prevalence ratio threshold <0·03), and the ratio of incident cases to deaths (incidence-to-mortality ratio threshold <1·0). Findings: In 2019, there were 36·8 million (95% uncertainty interval [UI] 35·1–38·9) people living with HIV worldwide. There were 0·84 males (95% UI 0·78–0·91) per female living with HIV in 2019, 0·99 male infections (0·91–1·10) for every female infection, and 1·02 male deaths (0·95–1·10) per female death. Global progress in incident cases and deaths between 2010 and 2019 was driven by sub-Saharan Africa (with a 28·52% decrease in incident cases, 95% UI 19·58–35·43, and a 39·66% decrease in deaths, 36·49–42·36). Elsewhere, the incidence remained stable or increased, whereas deaths generally decreased. In 2019, the global incidence-to-prevalence ratio was 0·05 (95% UI 0·05–0·06) and the global incidence-to-mortality ratio was 1·94 (1·76–2·12). No regions met suggested thresholds for progress. Interpretation: Sub-Saharan Africa had both the highest HIV burden and the greatest progress between 1990 and 2019. The number of incident cases and deaths in males and females approached parity in 2019, although there remained more females with HIV than males with HIV. Globally, the HIV epidemic is far from the UNAIDS benchmarks on progress metrics. Funding: The Bill & Melinda Gates Foundation, the National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH

The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019

Background: In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15–39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods: Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15–39 years to define adolescents and young adults. Findings: There were 1·19 million (95% UI 1·11–1·28) incident cancer cases and 396 000 (370 000–425 000) deaths due to cancer among people aged 15–39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59·6 [54·5–65·7] per 100 000 person-years) and high-middle SDI countries (53·2 [48·8–57·9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14·2 [12·9–15·6] per 100 000 person-years) and middle SDI (13·6 [12·6–14·8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23·5 million (21·9–25·2) DALYs to the global burden of disease, of which 2·7% (1·9–3·6) came from YLDs and 97·3% (96·4–98·1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation: Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Funding: Bill & Melinda Gates Foundation, American Lebanese Syrian Associated Charities, St Baldrick's Foundation, and the National Cancer Institute

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Introduction Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality. Methods Prospective cohort study in 109 institutions in 41 countries. Inclusion criteria: children <18 years who were newly diagnosed with or undergoing active treatment for acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma and neuroblastoma. Of 2327 cases, 2118 patients were included in the study. The primary outcome measure was all-cause mortality at 30 days, 90 days and 12 months. Results All-cause mortality was 3.4% (n=71/2084) at 30-day follow-up, 5.7% (n=113/1969) at 90-day follow-up and 13.0% (n=206/1581) at 12-month follow-up. The median time from diagnosis to multidisciplinary team (MDT) plan was longest in low-income countries (7 days, IQR 3-11). Multivariable analysis revealed several factors associated with 12-month mortality, including low-income (OR 6.99 (95% CI 2.49 to 19.68); p<0.001), lower middle income (OR 3.32 (95% CI 1.96 to 5.61); p<0.001) and upper middle income (OR 3.49 (95% CI 2.02 to 6.03); p<0.001) country status and chemotherapy (OR 0.55 (95% CI 0.36 to 0.86); p=0.008) and immunotherapy (OR 0.27 (95% CI 0.08 to 0.91); p=0.035) within 30 days from MDT plan. Multivariable analysis revealed laboratory-confirmed SARS-CoV-2 infection (OR 5.33 (95% CI 1.19 to 23.84); p=0.029) was associated with 30-day mortality. Conclusions Children with cancer are more likely to die within 30 days if infected with SARS-CoV-2. However, timely treatment reduced odds of death. This report provides crucial information to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer